loading
Precedente Chiudi:
$5.07
Aprire:
$5.05
Volume 24 ore:
122.23K
Relative Volume:
0.70
Capitalizzazione di mercato:
$92.37M
Reddito:
-
Utile/perdita netta:
$-22.38M
Rapporto P/E:
-3.1355
EPS:
-1.55
Flusso di cassa netto:
$-15.54M
1 W Prestazione:
-13.96%
1M Prestazione:
-35.89%
6M Prestazione:
-18.91%
1 anno Prestazione:
-39.29%
Intervallo 1D:
Value
$4.685
$5.1155
Intervallo di 1 settimana:
Value
$4.685
$5.73
Portata 52W:
Value
$4.685
$12.10

Nuvectis Pharma Inc Stock (NVCT) Company Profile

Name
Nome
Nuvectis Pharma Inc
Name
Telefono
360-837-7232
Name
Indirizzo
1 BRIDGE PLAZA, SUITE 275, FORT LEE
Name
Dipendente
13
Name
Cinguettio
Name
Prossima data di guadagno
2024-08-07
Name
Ultimi documenti SEC
Name
NVCT's Discussions on Twitter

Confronta NVCT con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
NVCT 4.8601 92.37M 0 -22.38M -15.54M -1.55
VRTX 449.35 115.43B 10.63B -479.80M -1.35B 13.33
REGN 749.22 82.04B 13.85B 4.65B 3.32B 35.06
ARGX 587.51 35.30B 1.86B -40.29M -1.28B -4.16
ALNY 247.60 32.04B 2.09B -332.26M 16.06M -4.14
BNTX 107.00 24.89B 3.30B -501.07M 1.03B 11.54

Nuvectis Pharma Inc Stock (NVCT) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2022-07-13 Iniziato Ladenburg Thalmann Buy

Nuvectis Pharma Inc Borsa (NVCT) Ultime notizie

pulisher
11:13 AM

Nuvectis Pharma stock hits 52-week low at $4.7 amid market challenges - Investing.com

11:13 AM
pulisher
07:25 AM

Nuvectis pharma officer Enrique Poradosu buys $9,980 in stock By Investing.com - Investing.com Australia

07:25 AM
pulisher
05:57 AM

Ron Bentsur Buys Handful Of Shares In Nuvectis Pharma - Simply Wall St

05:57 AM
pulisher
04:01 AM

Insider Buying: Nuvectis Pharma Inc (NVCT) Chairman & CEO Acquires Shares - GuruFocus.com

04:01 AM
pulisher
Nov 20, 2024

Nuvectis pharma officer Enrique Poradosu buys $9,980 in stock - Investing.com

Nov 20, 2024
pulisher
Nov 18, 2024

Nuvectis Pharma, Inc. (NASDAQ:NVCT) CEO Ron Bentsur Buys 20,000 Shares - MarketBeat

Nov 18, 2024
pulisher
Nov 18, 2024

Nuvectis pharma chairman buys $98,400 in common stock By Investing.com - Investing.com UK

Nov 18, 2024
pulisher
Nov 18, 2024

Nuvectis pharma chairman buys $98,400 in common stock - Investing.com

Nov 18, 2024
pulisher
Nov 15, 2024

Vitalli ends work on Daewoong asset; Alector’s $50M loan - Endpoints News

Nov 15, 2024
pulisher
Nov 15, 2024

Nuvectis Pharma reports data from Phase 1b study of NXP800 - Yahoo Finance

Nov 15, 2024
pulisher
Nov 14, 2024

Market Alert: Nuvectis Pharma reports promising data for NXP800 in Phase 1b; Advancing Towards Higher Dose Cohort - The Globe and Mail

Nov 14, 2024
pulisher
Nov 14, 2024

500: Something went wrong - Investing.com Canada

Nov 14, 2024
pulisher
Nov 14, 2024

Nuvectis Pharma CEO Says Increased Dose Intensity Needed To Drive More Efficacy From Ovarian Cancer Lead Drug - Yahoo Finance

Nov 14, 2024
pulisher
Nov 14, 2024

NVCT stock touches 52-week low at $5.05 amid market fluctuations - Investing.com India

Nov 14, 2024
pulisher
Nov 14, 2024

Nuvectis sinks after early-stage data for ovarian cancer therapy - MSN

Nov 14, 2024
pulisher
Nov 14, 2024

U.S. Stock market: Nuvectis Pharma declined by 40.58% while Sow Good was down by 55.30% during mid day trading - Business Upturn

Nov 14, 2024
pulisher
Nov 14, 2024

Nuvectis stock sinks on data for cancer drug (NVCT:NASDAQ) - Seeking Alpha

Nov 14, 2024
pulisher
Nov 14, 2024

Nuvectis Pharma Stock Plummets on Updated Data for Ovarian Cancer Study - MarketWatch

Nov 14, 2024
pulisher
Nov 14, 2024

Nuvectis Pharma Inc trading resumes - TipRanks

Nov 14, 2024
pulisher
Nov 14, 2024

U.S. Stock market: Nuvectis Pharma saw a sharp decline of 53.89% while AgEagle Aerial Systems surged by 133.74% in early trading - Business Upturn

Nov 14, 2024
pulisher
Nov 14, 2024

Nuvectis Pharma Reports Encouraging NXP800 Interim Data - GlobeNewswire

Nov 14, 2024
pulisher
Nov 14, 2024

Nuvectis Pharma Reports Encouraging NXP800 Interim Data Supporting Ongoing Enrollment in Phase - The Bakersfield Californian

Nov 14, 2024
pulisher
Nov 14, 2024

Nuvectis Pharma's NXP800 Shows Promise in Phase 1b Cancer Trial, New Dosing Success | NVCT Stock News - StockTitan

Nov 14, 2024
pulisher
Nov 14, 2024

Trading (NVCT) With Integrated Risk Controls - Stock Traders Daily

Nov 14, 2024
pulisher
Nov 14, 2024

Nuvectis Pharma (NASDAQ:NVCT) Announces Third Quarter 2024 Financial Results and Business Updates - Defense World

Nov 14, 2024
pulisher
Nov 13, 2024

Nuvectis Pharma (NVCT) Is a Great Choice for 'Trend' Investors, Here's Why - Yahoo Finance

Nov 13, 2024
pulisher
Nov 11, 2024

Wall Street Analysts Predict a 169.94% Upside in Nuvectis Pharma (NVCT): Here's What You Should Know - MSN

Nov 11, 2024
pulisher
Nov 08, 2024

Nuvectis Pharma's VP Michael Carson sells $22.5k in stock - Investing.com

Nov 08, 2024
pulisher
Nov 08, 2024

Nuvectis Pharma's VP Michael Carson sells $22.5k in stock By Investing.com - Investing.com UK

Nov 08, 2024
pulisher
Nov 08, 2024

FY2024 EPS Estimates for Nuvectis Pharma Raised by Analyst - Defense World

Nov 08, 2024
pulisher
Nov 07, 2024

FY2024 EPS Estimate for Nuvectis Pharma Increased by Analyst - MarketBeat

Nov 07, 2024
pulisher
Nov 07, 2024

Analysts Offer Predictions for Nuvectis Pharma Q1 Earnings - Defense World

Nov 07, 2024
pulisher
Nov 06, 2024

Roth Capital Comments on Nuvectis Pharma Q1 Earnings - MarketBeat

Nov 06, 2024
pulisher
Nov 05, 2024

Nuvectis Pharma Reports Improved Q3 Financials and Clinical Progress - TipRanks

Nov 05, 2024
pulisher
Nov 05, 2024

Nuvectis Pharma, Inc. Reports Third Quarter 2024 Financial Results and Business Highlights - GlobeNewswire

Nov 05, 2024
pulisher
Nov 03, 2024

Trend Tracker for (NVCT) - Stock Traders Daily

Nov 03, 2024
pulisher
Oct 28, 2024

Nuvectis Pharma's NXP900 Shows Promise in NSCLC Treatment, NXP800 Data Update Anticipated - Vancity Buzz

Oct 28, 2024
pulisher
Oct 28, 2024

PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update - Business Wire

Oct 28, 2024
pulisher
Oct 23, 2024

NVCTNuvectis Pharma, Inc. Latest Stock News & Market Updates - StockTitan

Oct 23, 2024
pulisher
Oct 23, 2024

Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2024 AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics - The Manila Times

Oct 23, 2024
pulisher
Oct 23, 2024

Nuvectis Pharma Announces Upcoming Presentations for NXP900 - GlobeNewswire

Oct 23, 2024
pulisher
Oct 20, 2024

Nuvectis Pharma (NASDAQ:NVCT) Is In A Good Position To Deliver On Growth Plans - Simply Wall St

Oct 20, 2024
pulisher
Oct 13, 2024

Marshall Wace LLP Has $214,000 Stock Holdings in Nuvectis Pharma, Inc. (NASDAQ:NVCT) - Defense World

Oct 13, 2024
pulisher
Oct 07, 2024

Nuvectis Pharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference - The Manila Times

Oct 07, 2024
pulisher
Oct 02, 2024

Learn to Evaluate (NVCT) using the Charts - Stock Traders Daily

Oct 02, 2024
pulisher
Sep 24, 2024

Here's Why We're Watching Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn Situation - Yahoo Finance

Sep 24, 2024
pulisher
Sep 21, 2024

(NVCT) Trading Advice - Stock Traders Daily

Sep 21, 2024
pulisher
Sep 19, 2024

Industry Update: 3 Exciting Precision Oncology Players to Watch - openPR

Sep 19, 2024
pulisher
Sep 18, 2024

A new trading data show Nuvalent Inc (NUVL) is showing positive returns. - SETE News

Sep 18, 2024
pulisher
Sep 18, 2024

What's Going On With Nuvve Stock? - Benzinga

Sep 18, 2024
pulisher
Sep 18, 2024

Rhumbline Advisers Has $3.18 Million Position in NVE Co. (NASDAQ:NVEC) - Defense World

Sep 18, 2024

Nuvectis Pharma Inc Azioni (NVCT) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Nuvectis Pharma Inc Azioni (NVCT) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
BENTSUR RON
Chairman & CEO
Nov 15 '24
Buy
4.92
20,000
98,400
3,266,424
Carson Michael J.
Vice President, Finance
Nov 07 '24
Sale
8.16
2,755
22,478
87,918
BENTSUR RON
Chairman & CEO
May 14 '24
Buy
6.74
1,940
13,076
3,246,424
BENTSUR RON
Chairman & CEO
May 10 '24
Buy
6.40
2,000
12,800
3,244,484
Poradosu Enrique
Chief Science & Business Off
May 10 '24
Buy
6.29
500
3,145
1,504,319
Shemesh Shay
Chief Dev. & Ops. Officer
May 10 '24
Buy
6.32
1,113
7,034
1,493,068
BENTSUR RON
Chairman & CEO
Mar 18 '24
Buy
10.29
5,000
51,450
3,242,484
$18.98
price up icon 1.80%
$70.68
price down icon 0.42%
$38.38
price up icon 3.49%
$369.83
price up icon 1.48%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Capitalizzazione:     |  Volume (24 ore):